Friday, August 26, 2022 9:40:38 AM
Extracted from the second quarter reports 2022, as stated by others not a 10-q it is a disclosure however it is a document required to be submitted to the SEC
During the six months ended June 30, 2022 (the "2022 Period"), the company realized $41,335 gross revenues compared to gross revenues of $0 during the six months ended June 30, 2021
Legal and Professional Fees and General and Administrative expenses increased in order to establish sales and operations, and to complete an audit in preparation for the company's SEC Form 1 that was filed on July 28, 2022.
Net loss for the 2022 Period was $6,347,736 compared to net loss of $49,880,221 for the 2021 Period.
The OTC Markets quarterly report can be accessed by going to the following link: https://www.otcmarkets.com/stock/COWI/disclosure
"This coming year, CarbonMeta plans to work closely with communities and investors; apply for state and federal grants; establish pilot projects that can generate economically sustainable hydrogen and high-value carbon products; and deliver carbon-negative building products that capture atmospheric CO2."
All my opinion and data extracted from OTC markets disclosure that can be verified by clicking the link above.
Good luck to all
Recent COWI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/01/2023 09:20:45 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 09:47:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 12:30:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/22/2023 07:13:47 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:00:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2023 12:35:32 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 07/17/2023 02:06:52 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 06/28/2023 06:46:02 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM